AMRI hires vp of chemical development

David Lathbury has more than 23 years of process development and optimisation experience

David Lathbury has joined AMRI as vice president of chemical development. He has taken over the leadership of AMRI’s Chemical Development business including operations in Albany, Rensselaer and Syracuse, New York.

He is also responsible for the coordination of global projects spanning all AMRI chemical development operations, including the company’s sites in Wales, UK and Hyderabad, India.

Lathbury has more than 23 years of experience in process development and optimisation, scale-up and technical transfer of products in the pharmaceutical and agrochemical industry. Most recently, he was director of process chemistry for AstraZeneca Process Research and Development (PR&D). Prior to this, he spent seven years at Smithkline Beecham Pharmaceutical’s Synthetic Chemistry division.

You may also like

Training & Education

Curia and Carterra partner on biologics symposium to further biotechnology research

The companies will run the high-throughput biologics symposium with a focus on the development of enhanced mouse systems for antibody generation and high-throughput single B cell screening
Research & Development

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA)
Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers
Manufacturing

Curia reveals continuous-flow collaboration with Corning

Continuous flow chemistry is critical for the development and manufacture of pharmaceutical intermediates and APIs
Research & Development

AMRI manufactures lipid excipients for Pfizer-BioNTech COVID-19 vaccine

AMRI has been providing development, scale-up and manufacturing services at a number of its global R&D and production sites for several months
Manufacturing

ViralClear partners with CDMO on potential COVID-19 treatment Merimepodib

ViralClear Pharmaceuticals has partnered with Albany Molecular Research Inc (AMRI) on the manufacture of Merimepodib API either as a stand-alone treatment or in combination with other antiviral agents or immune modulator
Manufacturing

AMRI to acquire Euticals

Strategic transaction expands API development and manufacturing business
Subscribe now